We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $604M
1-Year Est. Return 96.57%
This Fund
S&P 500
This Quarter Est. Return
-5.88%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$315M
AUM Growth
+$48.5M
Cap. Flow
-$4.73M
Cap. Flow %
-1.5%
Top 10 Hldgs %
69.9%
Holding
69
New
7
Increased
7
Reduced
7
Closed
20

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$30M
2
SNY icon
Sanofi
SNY
+$15.9M
3
COR icon
Cencora
COR
+$14.2M
4
SNN icon
Smith & Nephew
SNN
+$5.85M
5
SKIN icon
SkinHealth Systems
SKIN
+$3.75M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$10.4M
2
BIIB icon
Biogen
BIIB
+$7.32M
3
MDT icon
Medtronic
MDT
+$7.18M
4
SGHT icon
Sight Sciences
SGHT
+$6.52M
5
NTUS
Natus Medical Inc
NTUS
+$6.26M

Sector Composition

Rank Sector Weight
1 Healthcare 63.89%
2 Miscellaneous 26.34%
3 Financials 7.31%
4 Consumer Staples 2.47%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COR icon
1
Cencora
COR
$61.5B
$38.2M 12.14%
282,399
+99,065
+54% +$14.2M
APLS
2
PUT
DELISTED
Apellis Pharmaceuticals
APLS
$34.7M 11.02%
+507,700
New +$30M
GSK icon
3
GSK
GSK
$102B
$23.3M 7.39%
+790,600
New +$30M
MSAC
4
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
$23M 7.31%
2,323,000
– –
RLMD icon
5
PUT
Relmada Therapeutics
RLMD
$462M
$22.4M 7.13%
+606,200
New +$16.8M
RXDX
6
PUT
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$19.6M 6.23%
332,200
+230,600
+227% +$10.6M
BCYC
7
Bicycle Therapeutics
BCYC
$294M
$15.9M 5.05%
683,425
-5,564
-0.8% -$132K
OGN icon
8
Organon & Co
OGN
$3.61B
$14.7M 4.68%
628,836
+53,981
+9% +$1.63M
CI icon
9
Cigna
CI
$73.7B
$14.6M 4.64%
52,611
-423
-0.8% -$119K
SNY icon
10
Sanofi
SNY
$107B
$13.6M 4.31%
+356,888
New +$15.9M
INGN icon
11
Inogen
INGN
$146M
$12.7M 4.02%
521,295
-4,143
-0.8% -$114K
CNC icon
12
Centene
CNC
$32B
$9.88M 3.14%
127,011
-2,000
-2% -$179K
UTHR icon
13
United Therapeutics
UTHR
$22.1B
$9.41M 2.99%
44,959
+5,000
+13% +$1.12M
SKIN icon
14
SkinHealth Systems
SKIN
$89.1M
$7.77M 2.47%
658,964
+296,670
+82% +$3.75M
SNN icon
15
Smith & Nephew
SNN
$12.1B
$5.3M 1.69%
+228,390
New +$5.85M
VNDA icon
16
Vanda Pharmaceuticals
VNDA
$320M
$4.83M 1.54%
488,965
– –
PNT
17
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$4.21M 1.34%
544,545
+40,000
+8% +$340K
NARI
18
DELISTED
Inari Medical, Inc. Common Stock
NARI
$4.17M 1.33%
57,466
-55,000
-49% -$4.09M
UHS icon
19
Universal Health Services
UHS
$10.1B
$3.59M 1.14%
40,725
– –
EUCRU
20
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$2.49M 0.79%
248,674
– –
OBIO icon
21
Orchestra BioMed
OBIO
$311M
$2.48M 0.79%
250,000
– –
SYRE icon
22
Spyre Therapeutics
SYRE
$7.97B
$2.46M 0.78%
186,741
– –
XFOR icon
23
X4 Pharmaceuticals
XFOR
$401M
$2.43M 0.77%
47,282
+38,052
+412% +$1.31M
MODD icon
24
Modular Medical
MODD
$28.2M
$2.37M 0.75%
19,145
– –
CBAY
25
DELISTED
Cymabay Therapeutics
CBAY
$1.95M 0.62%
555,610
– –
1
2 3

Similar funds

EFL
ERn Financial LLC Middleton, Wisconsin $604M AUM 19.83% 1-Year Est. Return
V
VeraBank Henderson, Texas $604M AUM 23.32% 1-Year Est. Return
MAM
Morse Asset Management Darien, Connecticut $604M AUM 72.61% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $605M AUM 17.2% 1-Year Est. Return
AMG
Advisors Management Group La Crosse, Wisconsin $604M AUM 64.38% 1-Year Est. Return
VV
Verbena Value Westport, Connecticut $605M AUM
VCP
Varenne Capital Partners Paris, France $603M AUM 46.34% 1-Year Est. Return
EHI
Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return

Sio Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Sio Capital Management held 69 positions worth $315M, up 18% from $266M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Sio Capital Management's Q3 2022 filing shows 7 new, 7 increased, 7 reduced and 20 closed positions. Its largest new stake was GSK: 790,600 shares worth $23.3M. The largest sale was HCA Healthcare, an estimated $10.4M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 84% a quarter earlier, followed by Miscellaneous and Financials.

  • Sio Capital Management's largest Q3 2022 buy was GSK: 790,600 shares worth $23.3M.
  • Sio Capital Management added most to Cencora in Q3 2022, an estimated $14.2M increase.
  • Sio Capital Management's biggest Q3 2022 reduction was Inari Medical, Inc. Common Stock, cutting an estimated $4.09M.
  • Sio Capital Management fully exited HCA Healthcare in Q3 2022, selling an estimated $10.4M.
  • Sio Capital Management's ten largest holdings make up 70% of its $315M portfolio in Q3 2022.
  • Sio Capital Management opened 7 new positions and closed 20 in Q3 2022.
  • Sio Capital Management's portfolio value rose 18% quarter-over-quarter to $315M.

Based on Sio Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.